The invention provides crystalline forms of biphenyl-2-ylcarbamic acid 1-(2-{[4-(4-carbamoylpiperidin-1-ylmethyl)benzoyl]methylamino}ethyl)piperidin-4-ylester, and pharmaceutically acceptable solvates thereof. The crystalline formcan be a freebase, or a salt such as a diphosphate, monosulfate or dioxalatesalt. The invention also provides pharmaceutical compositions comprising thesecrystalline compounds or prepared using these compounds; processes andintermediates for preparing the crystalline compounds; and methods of usingthese compounds to treat a pulmonary disorder.